secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001193125-25-123141
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma CEO Robert Ang designated Principal Financial Officer and Principal Accounting Officer
--------------------------------------------------------------------------------

- Board designated CEO Robert Ang as principal financial and accounting officer effective May 19, 2025.
- No new compensation arrangements were entered into or amended in connection with the designation.
- Dr. Ang continues as President, CEO, and director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525123141/0001193125-25-123141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525123141/d927316d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-123141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer